Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice

Cancer Treatment Reviews

Volumn 23, Issue 3, 1997, Pages 153-169

  Freyer, G ^a   Ligneau, B ^a   Tranchand, B ^b   Ardiet, C ^b   Serre Debeauvais, F ^c   Trillet Lenoir, V ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE LÉON BÉRARD   (France)

^c HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL; VINCRISTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INTERACTION; DRUG MEGADOSE; HUMAN; HYPOPROTEINEMIA; KIDNEY DISEASE; LIVER DYSFUNCTION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHYSIOLOGY; PROGNOSIS; SHORT SURVEY; THROMBOCYTOPENIA; VOMITING;

EID: 0030745289     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90036-0     Document Type: Article

References (73)

1. Van Groeningen, C. J., Pinedo, H. M., Heddes, J. et al. (1988) Pharmacokinetics of 5-fluorouracil assessed with sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48: 6956-61.
2. Alberto, P. (1995) Dose-intensity in cancer chemotherapy. Bull. Cancer 82 (Suppl. 1): 3s-8s.
3. Gibaldi, M., Levy, G. (1976) Pharmacokinetics in clinical practice. J. Am. Med. Assoc. 235: 1864-67.
4. Benjamin, R. S., Wiernik, P. H. & Bachur, N. R. (1974) Adriamycin chemotherapy efficacy, safety and pharmacologic basis of an intermittent single high dosage schedule. Cancer 33: 19-27.
5. Tattersall, M. H. N., Parker, L. M., Pitman, S. W. & Frei, E. (1975) Clinical pharmacology of high-dose methotrexate. Cancer Chemother. Rep. 6: 25-9.
6. Monfardini, S. & Chabner, B. (1991) Joint NCI-EORTC consensus meeting on neoplasia in the elderly. Eur. J. Cancer 27: 653-4.
7. Cockcroft, D. W. & Gault, M. N. (1976) Prediction of creatinine clearance from serum creatinine. Nephron. 16: 31-41.
8. Freyer, G., Maire, P., Ardiet, C., Tranchand, B. & Droz, J. P. (1995) Chemotherapy in the elderly: present and future. Bull. Cancer 82: 531-40.
9. Verotta, D., Beal, S. L. & Sheiner, L. B. (1989) Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am. J. Physiol. 256: 1005-10.
10. Milano, G., Etienne, M. G., Ramaiolo, A. et al. (1994) Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol. 12: 1291-5.
11. Borsi, J. D. & Moe, P. J. (1987) Prognostic importance of systemic clearance of methotrexate in childhood. Cancer Chemother. Pharmacol. 19: 261-4.
12. Lind, M. J., Margison, J. M., Cerny, T. et al. (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother. Pharmacol. 25: 139-42.
13. Nakamura, E., Moritani, T. & Kanetaka, A. (1989) Biological age versus physical fitness age. Eur. J. Appl. Physiol. 58: 778-85.
14. Reece, P. H., Morris, R. G., Bishop, J. F. et al. (1987) Creatinine clearance as a predictor of ultrafiltrable platinum disposition in cancer patients treated with Cisplatinum: relationship between peak ultrafiltrable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 5: 304-9.
15. Calvert, A. H., Newell, D. R., Gumbrell, L. A. et al. (1987) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-56.
16. Chantier, C., Garnett, E. S., Parsons, V. et al. (1969) Glomerular filtration rate measurement in man by single injection method using Cr-EDTA. Clin. Sci. 37: 169-180.
17. Jodrell, D. I., Egorin, M. J., Caretta, R. M. et al. (1992) Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 10: 520-8.
18. Bleyer, W. A. (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41: 36-51.
19. Santini, J., Milano, G., Thyss, A. et al. (1989) 5-FU therapeutic monitoring with dose adjustment leads to improved therapeutic index in head and neck cancer. Br. J. Cancer 59: 287-90.
20. Sheiner, L. B. & Beal, S. L. (1981) Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharmaceut. 9: 503-12.
21. Hande, K. R., Wolff, S. N., Greco, F. A. et al. (1990) Etoposide kinetics in patients with obstructive jaundice. J. Clin. Oncol. 8: 1101-7.
22. Desai, Z. R., Van der Berg, H. W., Bridges, J. M. & Shanks, R. G. (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother. Pharmacol. 8: 211-14.
23. Launay, M. C., Milano, G., Iliadis, A. et al. (1989) A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br. J. Cancer 60: 89-92.
24. Favre, R., Monjanel, S., Alfonsi, M. et al. (1982) High-dose methotrexate: a clinical and pharmacokinetic evaluation. Cancer Chemother. Pharmacol. 9: 156-60.
25. Nirenberg, A., Mosende, C., Mehta, B. M. et al. (1977) High-dose methotrexate with citrovorum factor rescus: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat. Rep. 61: 779-83.
26. Du Bois, D. & Du Bois, E. F. (1916) A formula to estimate the approximate surface area if height and weight to be known. Arch. Int. Med. 17: 863-71.
27. Balis, F. M. (1986) Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin. Pharmacokinet. 11: 223-235.
28. Evans, W. E. (1988) Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose intensity. Blut. 56: 241-8.
29. Rodvold, K. A., Rushing, D. A. & Tewksbury, D. A. (1988) Doxorubicin clearance in the obese. J. Clin. Oncol. 6: 1321-7.
30. EORTC Pharmacokinetics and metabolism group. (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 23: 1083-7.
31. Schilsky, R. (1982) Renal and metabolic toxicities of cancer chemotherapy. Sem. Oncol. 9: 75-83.
32. Egorin, M. J. (1992) Therapeutic drug monitoring and dose optimization in Oncology. In: Workman, P., ed. New Approaches in Cancer Pharmacology: Drug Design and Development. Springer, Berlin, Heidelberg, New York, pp. 75-91.
33. Van Warmerdam, L. Van den Bemt, B., Ten Bokkel Huinink, W. et al. (1995) Dose individualisation in cancer chemotherapy: pharmacokinetic and pharmacodynamic relationships. Cancer Res. Ther. Control 4: 277-91.
34. Extra, J. M., Rousseau, F., Bruno, R. et al. (1993) Phase I and pharmacokinetic study of Taxotere given as a short intravenous infusion. Cancer Res. 53: 1037-42.
35. Kerr, I. G., Jolivet, J., Collins, J. M. et al. (1983) Test-dose for predicting high-dose methotrexate infusions. Clin. Pharmacol. Ther. 33: 44-51.
36. Launay-Iliadis, M. C., Bruno, R., Montay, G. et al. (1993) Population pharmacokinetics of Taxotere using non-parametric maximum likelihood (NPML) software. Eur. J. Drug Metab. Pharmacokinet. 18: 196 (Abst).
37. Bruno, R., Dorr, M. B., Montay, G. et al. (1994) Design and prospective implementation of population pharmacokinetic studies during the development of Docetaxel, a new anticancer drug. Clin. Pharmacol. Ther. 55: 2-35.
38. Kawato, Y., Aonuma, M., Hirato, Y et al. (1992) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-42. Biochem. Biophys. Res. Commun. 188: 70-7.
39. Catimel, G., Chabot, G. G., Guastalla, J. P. et al. (1995) Phase I and pharmacokinetic study of Irinotecan (CPT-11) administered daily for 3 days every 3 weeks in patients with advanced solid tumors. Ann. Oncol. 6: 133-40.
40. Chabot, G. G., Abigerges, D., Catimel, D. et al. (1995) Population pharmacokinetics and pharmacodynamics of Irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6: 141-151.
41. de Forni, M., Bugat, R., Chabot, G. G. et al. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204.
42. Canal, P., Gay, C., Dezeuze, A. et al. (1996) Pharmacokinetics and pharmacodynamics of Irinotecan during a phase II clinical trial in colorectal cancer. J. Clin. Oncol. 14: 2688-95.
43. Eksborg, S. (1989) Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin. Acta Oncol. 29: 339-42.
44. Ratain, M. J., Robert, J. & Van der Vigh, W. F. J. (1991) Limited sampling models for doxorubicin pharmacokinetics. J. Clin. Oncol. 9: 871-6.
45. Hryniuk, W. M. (1986) Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast carcinoma. JCO 4: 65-74.
46. Lena, N. (1987) Methotrexate test-dose protocol in the presence of 7-hydroxymethotrexate. Eur. J. Cancer Clin. Oncol. 23: 481-485.
47. Iliadis, A. & Bachir-Raho, M. (1985) Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J. Pharmacokin. Biopharm. 13: 101-115.
48. Newell, H., Calvert, H., Balmanno, K. et al. (1990) Carboplatin pharmacokinetics in children. Winter Meeting of the EORTC-PAM Group, Bordeaux, November.
49. Chatelut, E., Canal, P., Brunner, V. et al. (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 87: 573-80.
50. Ghazal-Aswad, S., Calvert, A. H. & Newell, D. R. (1996) A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother. Pharmacol. 37: 429-34.
51. Hayder, S., Lafolie, P., Bjorko, O. & Peterson, C. (1989) 6-Mercaptopurin plasma levels in children with acute leukemia: relation to relapse risk and myelotoxicity. Ther. Drug Monit. 11: 617-22.
52. Desoize, B., Marechal, F. & Cattan, A. (1990),Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumors. Br. J. Cancer 62: 840-1.
53. Piscitelli, S. C., Rodvold, K. A., Rushing, D. A. & Tewksburry, D. A. (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin. Pharmacol. Ther. 53: 555-61.
54. Evans, W. E., Crom, W. R., Abromovirch, M. et al. (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. New Engl. J. Med. 314: 471-7.
55. Stewart, C. F., Arbuck, S. G., Fleming, R. A. & Evans, W. E. (1991) Relation of systemic exposure to unbound etoposide and hematologica toxicity. Clin. Pharmacol. Ther. 50: 385-93.
56. Rustum, Y. M., Riva, R. C. & Preisler, H. D. (1987) Pharmacokinetic parameters of Ara-C and their relationship to intracellular metabolism of Ara-C, toxicity and response of patients with acute non lymphocytic leukemia treated with conventional and high-dose Ara-C. Sem. Oncol. 14: 141-8.
57. Longnecker, S. M., Donehower, R. C., Cates, A. E. et al. (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat. Rep. 71: 53-9.
58. Gamelin, E. (1994) Intensified chemotherapy of metastatic colorectal cancer with individual adaptation of 5-fluorouracil dose. Proc. Am. Assoc. Cancer Res. 35: 411.
59. Kearns, C., Gianni, L., Capri, G., Gianni, A. & Egorin, M. (1994) A comprehensive pharmacokinetic (PK) model of paclitaxel and 6-OH paclitaxel with application to pharmacodynamic (PD) relationship in humans. Proc. Am. Soc. Clin. Oncol. 13: 134.
60. Le Blanc, G. & Waxman, D. (1989) Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Met. Rev. 20: 395-439.
61. Jelliffe, R. W., Schumitzky, A. et al. (1993) Individualizing drug dosage regimens: role of population pharmacokinetic and dynamic models, bayesian fitting and adaptative control. Ther. Drug Monitoring 15: 380-93.
62. Boeckmann, A. J., Sheiner, L. B. & Beal, S. L. (1992) NONMEM users guides, part V: introductory guide. Technical Report of the Division of Clinical Pharmacology, University of California. San Francisco: University of California.
63. Bressolle, F., Ray, P., Jacquet, J. M. et al. (1991) Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother. Pharmacol. 29: 53-60.
64. Ratain, M. J., Mick, R., Schilsky, R. L., Vogelzang, N. J. & Berezin, F. (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol. 9: 1480-6.
65. Collins, J. M., Zaharko, D. S., Dedrick, R. L. & Chabner, B. A. (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 70: 73-80.
66. Collins, J. M. (1988) Improving the use of anticancer drugs: clinical pharmacokinetic approaches. Is. J. Med. Sci. 24: 483-7.
67. Egorin, M. J., Echo van D. A., Tipping, S. J. et al. (1984) Pharmacokinetics and dosage reduction of cisplatinum in patients with impaired renal function. Cancer Res. 44: 5432-8.
68. Ratain, M. J., Schilsky, R. L., Conley, B. A. & Egorin, M. J. (1990) Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8: 1739-53.
69. Sonnichsen, D., Ribeiro, R., Luo, X. et al. (1994) Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide (VP-16) in pediatric solid tumor patients. Proc. Am. Soc. Clin. Oncol. 13: 140.
70. Stoller, R. G., Hande, K. R., Jacobs, S. A. et al. (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med. 297: 630-4.
71. Tranchand, B., Point, Y. D., Minuit, M. P. et al. High-dose melphalan adjustment: possibility of using a test-dose. Cancer Chemother. 23: 95-100.
72. Ackland, S. P., Ratain, M. J., Vogelzang, N. J. et al. (1989) Pharmacokinetics and pharmacodynamics of long-term continuous-infusion Doxorubicin. Clin. Pharmacol. Ther. 45: 340-347.
73. Pinkel, D. (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18: 853-6.